Presentation is loading. Please wait.

Presentation is loading. Please wait.

Dosimetric Consequences of 3D Versus 4D PET/CT for Target Delineation of Lung Stereotactic Radiotherapy  Shankar Siva, MBBS, FRANZCR, Brent Chesson, BAppSc.

Published byAurore Cormier Modified over 6 years ago

Similar presentations

Presentation on theme: "Dosimetric Consequences of 3D Versus 4D PET/CT for Target Delineation of Lung Stereotactic Radiotherapy  Shankar Siva, MBBS, FRANZCR, Brent Chesson, BAppSc."— Presentation transcript:

1 Dosimetric Consequences of 3D Versus 4D PET/CT for Target Delineation of Lung Stereotactic Radiotherapy  Shankar Siva, MBBS, FRANZCR, Brent Chesson, BAppSc (Hons), Jason W. Callahan, BAppSc (Hons), Nicholas Hardcastle, PhD, Lisa Crawford, BAppSc, Phillip Antippa, MBBS, FRACS, Gavin Wright, MBBS, FRACS, Michael P. MacManus, MD, MRCP, FRANZCR, Rodney J. Hicks, MD, MBBS, FRACP, Tomas Kron, PhD, David L. Ball, MD, MBBS, FRANZCR  Journal of Thoracic Oncology  Volume 10, Issue 7, Pages (July 2015) DOI: /JTO Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 The 4D positron emission tomography (PET)/computed tomography (CT) acquisition (above) and 3D PET/CT acquisition (below) in a patient with a lower lobe tumor, demonstrating CT images (left), PET images (middle), and coregistered PET/CT images (right). Journal of Thoracic Oncology  , DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Dosimetric Consequences of 3D Versus 4D PET/CT for Target Delineation of Lung Stereotactic Radiotherapy  Shankar Siva, MBBS, FRANZCR, Brent Chesson, BAppSc."

Similar presentations

Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD 

Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD 
Evaluation of 18F-FDG PET-CT for Differentiation of Pulmonary Pathology in an Approach of Outpatient Fast Track Assessment  Tjeerd S. Aukema, MD, Renato.

Evaluation of 18F-FDG PET-CT for Differentiation of Pulmonary Pathology in an Approach of Outpatient Fast Track Assessment  Tjeerd S. Aukema, MD, Renato.
Jeffrey Bradley, MD  Journal of Thoracic Oncology 

Jeffrey Bradley, MD  Journal of Thoracic Oncology 
Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer

Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer
Lungs on Fire Journal of Thoracic Oncology

Lungs on Fire Journal of Thoracic Oncology
It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible  Alessandro Brunelli,

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible  Alessandro Brunelli,
Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Paraneoplastic Opsoclonus-Myoclonus Syndrome as a New and Single Manifestation of Relapsing Disease in a Patient with Small Cell Lung Cancer  Ernest Nadal,

Paraneoplastic Opsoclonus-Myoclonus Syndrome as a New and Single Manifestation of Relapsing Disease in a Patient with Small Cell Lung Cancer  Ernest Nadal,
Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D
MET-Mutated NSCLC with Major Response to Crizotinib

MET-Mutated NSCLC with Major Response to Crizotinib
Stereotactic Radiotherapy for Pulmonary Oligometastases: A Systematic Review  Shankar Siva, MBBS, Michael MacManus, MD, MRCP, FRCR, FRANZCR, David Ball,

Stereotactic Radiotherapy for Pulmonary Oligometastases: A Systematic Review  Shankar Siva, MBBS, Michael MacManus, MD, MRCP, FRCR, FRANZCR, David Ball,
Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes  Julie E. Bauman, MD, Michael.

Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes  Julie E. Bauman, MD, Michael.
KRAS Mutation Analysis Helps to Differentiate Between Pulmonary Metastasis from Colon Adenocarcinoma In Situ and Primary Lung Adenocarcinoma  Taylor M.

KRAS Mutation Analysis Helps to Differentiate Between Pulmonary Metastasis from Colon Adenocarcinoma In Situ and Primary Lung Adenocarcinoma  Taylor M.
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer  Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer  Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,
Patient-Reported Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer  Frank J. Lagerwaard, MD, PhD, Neil K. Aaronson,

Patient-Reported Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer  Frank J. Lagerwaard, MD, PhD, Neil K. Aaronson,
Pulmonary botryomycosis: A difficult diagnosis in the preoperative patient  Russell Hodgson, MBBS, Shane A. Blackmore, MBBS, C. Peter Clarke, FRACS  The.

Pulmonary botryomycosis: A difficult diagnosis in the preoperative patient  Russell Hodgson, MBBS, Shane A. Blackmore, MBBS, C. Peter Clarke, FRACS  The.
Primary Tracheal Lymphoma Causing Respiratory Failure

Primary Tracheal Lymphoma Causing Respiratory Failure
Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Similar presentations

Ads by Google